<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3262">
  <stage>Registered</stage>
  <submitdate>17/08/2011</submitdate>
  <approvaldate>17/08/2011</approvaldate>
  <nctid>NCT01420042</nctid>
  <trial_identification>
    <studytitle>Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration</studytitle>
    <scientifictitle>A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NNZ-2566 in Healthy Subjects, Following Oral Administration</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Neu-2566-HV-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain Injuries, Traumatic</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - NNZ-2566
Treatment: drugs - Placebo

Placebo Comparator: Placebo (lemon flavoured cordial) - NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.

Experimental: NNZ-2566 - 


Treatment: drugs: NNZ-2566
Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.

Treatment: drugs: Placebo
Lemon flavoured cordial and Water for Injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events (AE) and serious adverse events (SAE)</outcome>
      <timepoint>Through to Day 7 post end of study drug administration or until resolved</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males: 60.0-100.0 kg, Females: 50.0-100.0 kg (inclusive).

          -  Males: Body mass index (BMI) of 20-30.0, Females: BMI of 18.5-30.0 kg/m2 (inclusive).

          -  Healthy, determined by a medical history with particular attention to:

               -  drug history identifying any known drug allergies and the presence of drug abuse;

               -  any chronic use of medication

               -  thorough review of body systems: no clinically significant abnormal findings on
                  physical examination and electrocardiogram (ECG),

          -  Adequate venous access in arms to allow collection of blood samples.

          -  Fluent in the English language.

          -  Have voluntarily given written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Pregnant and lactating females.

          -  History of allergy/hypersensitivity to any of the ingredients of the formulations

          -  History of clinically significant gastrointestinal, hepatic, renal, cardiovascular,
             dermatological, immunological, respiratory, endocrine, oncological, neurological,
             metabolic, gynecological, ENT or musculoskeletal disorders, psychiatric disease or
             hematological disorders.

          -  Any history of asthma during the last 10 years.

          -  Creatinine clearance &lt;65 mL/min.

          -  Any predisposing condition that might interfere with the absorption, distribution,
             metabolism, and/or excretion of the investigational product.

          -  History of abnormal bleeding tendencies or thrombophlebitis unrelated to venepuncture.

          -  History of hepatitis B, a positive test for hepatitis B surface antigen, a history of
             hepatitis C, a positive test for hepatitis C antibody, a history of HIV infection or
             demonstration of HIV antibodies.

          -  Any evidence of organ dysfunction, or any clinically significant clinical laboratory
             value which, in the opinion of the Investigator would jeopardize the safety of the
             subject or impact on the validity of the study results, including a liver function
             test (LFT) &gt;1.5 x upper limit of normal (ULN).

          -  Those who may have difficulty abstaining from alcohol during the 48 hr prior to dose
             administration and until completion of the Study Exit visit.

          -  History of, or current evidence of, abuse of alcohol or any drug substance, licit or
             illicit, or positive urine drug screen for drugs of abuse.

          -  Difficulty in abstaining from any prescription medications for 14 days prior to dose
             administration and for the duration of the study.

          -  Difficulty in abstaining from over-the-counter (OTC) medications or herbal supplements
             for 14 days prior to dose administration and for the duration of the study, (with the
             exception of occasional analgesia, vitamin and other nutrient supplement use, at the
             discretion of the Investigator).

          -  Difficulty in abstaining from food and/or beverages that contain caffeine or other
             xanthines, (e.g. coffee, tea, cola and chocolate) during the 48 hrs prior to dose
             administration and for the duration of the study.

          -  History of any psychiatric illness which may impair the ability to provide written
             informed consent.

          -  Poor compliers or those unlikely to attend.

          -  Receipt of any drug as part of a research study within 30 days of initial dose
             administration in this study.

          -  Standard blood donation (usually 550 mL) within the 12-week period before dose
             administration.

          -  Unusual dietary habits and excessive or unusual vitamin intakes.

          -  Vaccination or immunizations within 30 days of initial dose administration.

          -  Whilst there were no QT/QTc effects seen in the human volunteers at a dose of 20 mg/kg
             administered intravenously as a 10 min infusion, until the effects of the drug on
             QT/QTc interval have been formally characterized, the study will use the exclusion
             criteria defined in International Conference on Harmonisation (ICH) Guideline E14 to
             exclude subjects with a risk of QT/QTc prolongation, namely:

               -  A marked baseline prolongation of corrected QT interval &gt;450 ms in two ECGs, or

               -  A history of risk factors for Torsade de Pointes (e.g., heart failure,
                  hypokalemia, family history of Long QT Syndrome).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>24</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Neuren Pharmaceuticals Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to obtain evidence of safety and determine the pharmacokinetics
      (PK) of NNZ-2566 in healthy volunteers, when administered orally.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01420042</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Maggie Scott</name>
      <address>Neuren Pharmaceuticals Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>